Literature DB >> 7247354

Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.

M A French, F B Cerra, M E Plaut, J J Schentag.   

Abstract

Twenty-five critically ill adults receiving blood level-adjusted doses of amikacin were prospectively studied with serum, urine, and, when possible, tissue amikacin concentrations. These data were fitted to a two-compartment pharmacokinetic model. Prolonged urine collections or postmortem tissues (or both) were used to confirm predicted tissue accumulation. Nephrotoxicity was also investigated. Patients were defined as having renal damage if they showed an increase in serum creatinine of greater than 0.5 mg/100 ml, an increase in urine beta 2-microglobulin of greater than 50 mg/day, and presence of urinary casts of greater than 500/ml. Renal damage was attributed to amikacin if there was, in addition to the above, tissue accumulation of amikacin of greater than 600 mg. These patients were matched with 25 patients treated with gentamicin during the same time period. There were no statistical differences between the gentamicin- and amikacin-treated patients in age, sex, weight, base-line creatinine clearance, concurrent cephalosporins or diuretics, treatment duration, site of infection, normalized (amikacin/gentamicin dosing ratio of 3:1) total dose, mortality, or tissue accumulation. More amikacin-treated patients (19 of 25) than gentamicin-treated patients (9 of 25) received prior aminoglycosides (P less than 0.01). The only pharmacokinetic parameter that differed between amikacin and gentamicin was a greater K21 for gentamicin. Nephrotoxicity was observed in 4 gentamicin was a greater K21 for gentamicin. Nephrotoxicity was observed in 4 gentamicin-treated patients (16%) and 5 amikacin-treated patients (20%). At a 3:1 dosing ratio, there were no significant differences between amikacin and gentamicin two-compartment pharmacokinetics and nephrotoxic potential in matched critically ill patients, but the trend of these data showed greater amikacin tissue accumulation. However, at an amikacin/gentamicin dosing ratio of 4:1, their tissue accumulation potential appeared to be almost identical.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247354      PMCID: PMC181374          DOI: 10.1128/AAC.19.1.147

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Gentamicin blood levels: a guide to nephrotoxicity.

Authors:  J G Dahlgren; E T Anderson; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

2.  Concentrations of gentamicin and amikacin in human kidneys.

Authors:  C Q Edwards; C R Smith; K L Baughman; J F Rogers; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin.

Authors:  P Loirat; J Rohan; A Baillet; F Beaufils; R David; A Chapman
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

4.  Letter: Prolonged excretion of gentamicin in a patient with umimpaired renal function.

Authors:  G Kahlmeter; G Kamme
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

5.  Comparative pharmacokinetics of amikacin and kanamycin.

Authors:  J T Clarke; R D Libke; C Regamey; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

6.  Comparative tissue accumulation of gentamicin and tobramycin in patients.

Authors:  J J Schentag; G Lasezkay; M E Plaut; W J Jusko; T J Cumbo
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

7.  Gentamicin disposition and tissue accumulation on multiple dosing.

Authors:  J J Schentag; W J Jusko; J W Vance; T J Cumbo; E Abrutyn; M DeLattre; L M Gerbracht
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

8.  Controlled comparison of amikacin and gentamicin.

Authors:  C R Smith; K L Baughman; C Q Edwards; J F Rogers; P S Lietman
Journal:  N Engl J Med       Date:  1977-02-17       Impact factor: 91.245

9.  Tissue persistence of gentamicin in man.

Authors:  J J Schentag; W J Jusko; M E Plaut; T J Cumbo; J W Vance; E Abrutyn
Journal:  JAMA       Date:  1977-07-25       Impact factor: 56.272

10.  Accumulation pharmacokinetics of tobramycin.

Authors:  J J Schentag; G Lasezkay; T J Cumbo; M E Plaut; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

View more
  13 in total

Review 1.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 2.  Pharmacokinetics and pharmacodynamics in critically ill patients.

Authors:  H J Mann; D W Fuhs; F B Cerra
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

3.  Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.

Authors:  C Burdet; O Pajot; C Couffignal; L Armand-Lefèvre; A Foucrier; C Laouénan; M Wolff; L Massias; F Mentré
Journal:  Eur J Clin Pharmacol       Date:  2014-10-21       Impact factor: 2.953

4.  Multiple-dose non-linear regression analysis program. Aminoglycoside dose prediction.

Authors:  J R Koup; T Killen; L A Bauer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 5.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

6.  Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers.

Authors:  N E Winslade; M H Adelman; E J Evans; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock.

Authors:  W Picard; F Bazin; B Clouzeau; H-N Bui; M Soulat; E Guilhon; F Vargas; G Hilbert; S Bouchet; D Gruson; N Moore; A Boyer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

Review 8.  Comparison of drug dosing methods.

Authors:  M E Burton; M R Vasko; D C Brater
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

Review 9.  Serum level monitoring of antibacterial drugs. A review.

Authors:  M Wenk; S Vozeh; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 10.  Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?

Authors:  Alexandre Duong; Chantale Simard; Yi Le Wang; David Williamson; Amélie Marsot
Journal:  Antibiotics (Basel)       Date:  2021-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.